Navigation Links
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial

severity of hot flashes than the lower dose.

In secondary analyses, the percent of women reporting greater than 50% reduction in all hot flashes was statistically significantly higher in the MF101 high dose group compared to placebo (p=0.03) and in both doses of MF101 combined compared to placebo (p=0.05).

MF101 is a novel estrogen receptor beta agonist that is expected not to stimulate the endometrium or breast tissue. Safety analyses showed no cases of endometrial hyperplasia or uterine cancer during the trial and there were no differences in incidence of vaginal bleeding between the placebo group and the two cohorts treated with MF101. The only side effect that increased with MF101 treatment was loose stool/diarrhea (12% in each of the drug arms vs. 3% in placebo arm). Constipation was improved with MF101 therapy. These observations are consistent with the presence of soluble fiber in the drug extract, which future optimization of the manufacturing process will significantly reduce. Adherence to the study medication was high with 91% of the participants compliant with treatment after 12 weeks of therapy.

"I am very encouraged and pleased by the findings of this clinical trial," said Deborah Grady, M.D., Associate Dean for Clinical and Translational Science, Professor of Medicine and Director of the University of California, San Francisco (UCSF) Women's Health Clinical Research Center. "The combination of a trend to better efficacy with a higher dose of MF101 and a very strong safety profile of a drug that was very well tolerated by menopausal women is exciting news. These early positive clinical results are not only encouraging for discovering a safer therapy for hot flashes but also support the role of estrogen receptor beta as a novel target for treating menopausal symptoms."

"Recent clinical trials, such as the HERS and the WHI, elucidated important safety concerns of postmenopau
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:5/21/2013)... 21, 2013  Armada Health Care (Armada) is ... Armada corporate website ( www.armadahealthcare.com ).  This new ... and first-to-market services and its position as the ... specialty pharmacy industry. The updated website ... business model in delivering an extensive portfolio of ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... embedded-ultrasound platform, today announced the introduction of ... allows complete network-based communications with all cQuest ... latest embedded-ultrasound technology, including this new capability, ... Sao Paulo, Brazil from May ...
(Date:5/21/2013)... Hurel Corporation ("Hurel"), a world-leading provider of ... today announced the appointment of James S. ... of Directors. Dr. MacDonald is the former Executive Vice ... ("SPRI"), which was the pharmaceutical development arm of Schering ... in 2009. Over a career that has ...
Breaking Medicine Technology:Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... AUSTIN, Texas, July 6, 2011 Ascension Orthopedics, Inc., a ... of the TITAN Inset Mini Glenoid. The Mini Glenoid is ... can now provide a unique way to address glenoid arthritis. ... resurface the central portion of the glenoid as well as ...
... Allure Medical Spa released an iPhone application to teach ... visualize potential outcomes. "Many of my patients are tech-savvy ... board certified cosmetic surgeon, Dr. Brett Kotlus at Allure. ... palm of their hands that describes the range of ...
Cached Medicine Technology:Ascension Orthopedics Announces Market Release of TITAN™ Inset Mini Glenoid 2Cosmetic Surgery iPhone App Teaches and Amuses 2
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... Arizona State University is seeking aspiring ... their ideas into solutions, products and services in ... is recruiting participants for AREA48 (Applied Regional Economic ... early-stage entrepreneurs with opportunities to access human and ... ASU is particularly seeking participation from retirees, veterans ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...
(Date:5/21/2013)... 21, 2013 Global Proving Ground (GPG), ... the largest online retailer of health and fitness supplements, ... sports show, Warrior Island. “We cast the show ... & Twitter, with our unique social networking platform,” states ... elite fighters on an island in the Pacific Ocean, ...
Breaking Medicine News(10 mins):Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... Center have identified and announced the most common causes ... with red, sore itchy rashes was caused by exposing ... fragnance, cosmetics, metals, creams, etc. ,The July ... 10 causes of contact dermatitis that were recently identified ...
... tests conducted by the Analytical Services Tasmania King Island's water ... conducted tests which showed high content of lead in the ... testing done by the council which found no problem with ... metals and the results were announced with days of testing. ...
... report of the Washington Post, the department of health of Washington, ... every district resident, between 14years and 84years, to ... , The launching of the campaign, to be named ... the 12th annual National HIV Testing Day. ,Gregg Pane, ...
... (AIIMS) dean is considering quitting the institution //, as ... colleagues and misguided students. ,The dean R.C.Deka, ... expert in cochlear implant surgery is now contemplating leaving ... by his colleagues and students. He explained that he ...
... in their new studies that the analysis of the placenta ... ,Scientists from the University of Yale stated that they believe ... birth by analysing and seeking out certain biological abnormalities present ... developmental disorder that affects a child's social learning and communication ...
... Varca in Goa it is found that Indians eating ... //The two day conference mainly analyzed the Indian population ... This would further worsen the situation by increasing the ... diabetes and other fatal diseases. Experts and medical practitioners ...
Cached Medicine News:Health News:Another Senior Doctor From AIIMS Contemplates Leaving Due to Infighting 2Health News:Another Senior Doctor From AIIMS Contemplates Leaving Due to Infighting 3Health News:Analysis of Placenta Helps In Diagnosis of Autism At Birth 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: